Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.43 |
| ▸ | ESR1 | P03372 | 6/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3000884 | 0.87 | SERPINE1 (0.62) | SERPINE1KMT2AMEN1MAPTTDP1 | |
| SCHEMBL30821431 | 0.87 | SERPINE1 (0.62) | SERPINE1KMT2AMEN1MAPTTDP1 | |
| SCHEMBL3006064 | 0.85 | SERPINE1 (0.48) | SERPINE1KMT2AMEN1MAPTTDP1 | |
| SCHEMBL9750105 | 0.84 | ALOX5 (0.59) | SERPINE1KMT2AMEN1MAPTCA12 | |
| SCHEMBL2995722 | 0.84 | KMT2A (0.47) | SERPINE1KMT2AMEN1MAPTTDP1 | |
| SCHEMBL8756335 | 0.82 | SERPINE1 (0.50) | SERPINE1KMT2AMEN1MAPTNSD2 | |
| SCHEMBL3000109 | 0.82 | SERPINE1 (0.51) | SERPINE1KMT2AMEN1MAPTTDP1 | |
| SCHEMBL3005634 | 0.81 | ESR1 (0.57) | SERPINE1KMT2AMEN1MAPTNSD2 | |
| SCHEMBL8756031 | 0.80 | ESR1 (0.50) | SERPINE1KMT2AMEN1MAPTCA12 | |
| SCHEMBL13286773 | 0.78 | SERPINE1 (0.70) | SERPINE1KMT2AMEN1MAPTNSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190856-A1 | Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2010-07-29 | — | — | US | claimed |
| EP-2019091-A1 | Novel polyhydroxylated compounds as Fatty Acid Synthase (FASN) inhibitors | Fundació Privada Institut d'Investigació Biomédica de Girona - Dr. Josep Trueta (ES) | 2009-01-28 | — | — | EP | claimed |
| US-20100190856-A1 | Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2010-07-29 | — | — | US | disclosed |
| US-20100190856-A1 | Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2010-07-29 | — | — | US | disclosed |
| US-20100190856-A1 | Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2010-07-29 | — | — | US | disclosed |
| EP-2019091-A1 | Novel polyhydroxylated compounds as Fatty Acid Synthase (FASN) inhibitors | Fundació Privada Institut d'Investigació Biomédica de Girona - Dr. Josep Trueta (ES) | 2009-01-28 | — | — | EP | disclosed |
| EP-2019091-A1 | Novel polyhydroxylated compounds as Fatty Acid Synthase (FASN) inhibitors | Fundació Privada Institut d'Investigació Biomédica de Girona - Dr. Josep Trueta (ES) | 2009-01-28 | — | — | EP | disclosed |
| WO-2009000864-A1 | NOVEL POLYHYDROXYLATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS | FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE GIRONA DR. JOSEP TRUETA (ES) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190856-A1 | Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors | FASN, SCD, FADS2 | SERPINE1 1776/4885KMT2A 3556/4885MEN1 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.